Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines
about
New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancinThe Role of Staphylococcus aureus Virulence Factors in Skin Infection and Their Potential as Vaccine AntigensPhotothermal killing of Staphylococcus aureus using antibody-targeted gold nanoparticles.Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure InfectionsPharmacokinetics of tedizolid in subjects with renal or hepatic impairment.Colonization with Multi-Drug Resistant Organisms in Nursing Homes: Scope, Importance, and ManagementAnalysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infectionsSystematic Review and Meta-Analysis To Estimate Antibacterial Treatment Effect in Acute Bacterial Skin and Skin Structure Infection.A Prescription for Resistance: Management of Staphylococcal Skin Abscesses by General Practitioners in Australia.Moxifloxacin in complicated skin and skin structure infections (cSSSIs): A prospective, international, non-interventional, observational study.Combination of extracts from Aristolochia cymbifera with streptomycin as a potential antibacterial drugThe potential role of nemonoxacin for treatment of common infections.Current and emerging drugs for acute bacterial skin and skin structure infections: an update.Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials.Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).The times they are a-changin': new antibacterials for skin and skin structure infections.Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.Linezolid: a promising option in the treatment of Gram-positives.Update on management of skin and soft tissue infections in the emergency department.Transitions of care in the management of acute bacterial skin and skin structure infections: a paradigm shift.Hospital admission patterns in adult patients with skin and soft tissue infections: Identification of potentially avoidable hospital admissions through a retrospective database analysis.Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure.Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin.Single Intravenous Dose of Oritavancin for the Treatment of Gram-positive Acute Bacterial Skin and Skin Structure Infections: Summary of Safety from the Phase 3 SOLO studies.Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate in Elderly Subjects.
P2860
Q26764885-1C5040E2-AF10-4FE3-BC8E-FB9D2D6CE21FQ26768436-105F9DAA-7359-4D29-BB9A-12F53BB90490Q30415264-D249339B-9EBC-4C23-B44D-EC2750925008Q33726674-E404C836-8999-47C4-B976-9CDB7C411795Q34596658-B42343B5-F812-4016-B81D-C966D48AEC3DQ35049907-347983C2-662F-4C49-92E8-0F96936F3811Q35105971-25D54863-9622-4A8B-9478-EE6794BD6314Q35860102-859482C8-1452-4656-86A0-453A2C133D00Q36969916-711D1B67-8E39-4506-BF32-01263EF0DCDFQ36997690-735B21DB-58DE-4015-83B2-031E4D8CDD42Q37165462-53D6B5C3-1D35-4A98-BB6E-37CB38F97D93Q37842543-0BE4E6D2-210D-4A0E-BBB4-FEEA16460FC5Q38242081-D4C5B98A-8B40-47BF-A3C3-4831EA299172Q38379887-F1377614-CF60-448B-86BF-96639080C7B2Q38394008-98651977-99FB-4901-905C-80FBB4709727Q38438503-F1F208EE-41CF-4B60-A8D7-4BD5399FA5C2Q38536284-B4BF5E96-CE62-469C-9BEE-1AA53636BF5CQ39044932-E8BA08ED-52FA-49A7-9490-0CAAFE023D05Q39165124-157CBEA8-292F-46DF-9FE6-32174D9F4B8DQ39719043-BC53D87F-58F6-408B-90C8-EC2814CB3157Q40680089-23FFBB44-8EDF-418D-AAE8-33BA9A36FC01Q41665025-653A6D96-4134-4DC5-A2F8-CB06B2F006C9Q41681175-87B9158A-BEE1-4CCE-AF42-6A0C664EE5DBQ41858535-6818F7CC-8F66-40D7-9588-D2DBB01184E5Q49874661-15EB6E39-1DA7-43D7-911E-E63AF0C8E06EQ50104909-B2A51C21-9D0E-4EEA-B65C-68554BD87340
P2860
Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Acute bacterial skin infection ...... y of America (IDSA) guidelines
@ast
Acute bacterial skin infection ...... y of America (IDSA) guidelines
@en
Acute bacterial skin infection ...... y of America (IDSA) guidelines
@nl
type
label
Acute bacterial skin infection ...... y of America (IDSA) guidelines
@ast
Acute bacterial skin infection ...... y of America (IDSA) guidelines
@en
Acute bacterial skin infection ...... y of America (IDSA) guidelines
@nl
prefLabel
Acute bacterial skin infection ...... y of America (IDSA) guidelines
@ast
Acute bacterial skin infection ...... y of America (IDSA) guidelines
@en
Acute bacterial skin infection ...... y of America (IDSA) guidelines
@nl
P2093
P3181
P1476
Acute bacterial skin infection ...... y of America (IDSA) guidelines
@en
P2093
David A. Talan
Frank LoVecchio
Fredrick M. Abrahamian
Gregory J. Moran
P304
P3181
P356
10.1016/J.JEMERMED.2012.11.050
P407
P577
2013-06-01T00:00:00Z